{"id":"https://openalex.org/W4396932271","doi":"https://doi.org/10.1158/0008-5472.c.7234905","title":"Data from ATG-101 Is a Tetravalent PD-L1\u00d74-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1\u2013Directed 4-1BB Activation","display_name":"Data from ATG-101 Is a Tetravalent PD-L1\u00d74-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1\u2013Directed 4-1BB Activation","publication_year":2024,"publication_date":"2024-05-15","ids":{"openalex":"https://openalex.org/W4396932271","doi":"https://doi.org/10.1158/0008-5472.c.7234905"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.c.7234905","doi":"https://doi.org/10.1158/0008-5472.c.7234905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.7234905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/0008-5472.c.7234905","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030401301","display_name":"Hui Yuwen","orcid":"https://orcid.org/0009-0002-1326-7954","observed_orcids":["https://orcid.org/0009-0002-1326-7954"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hui Yuwen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-1326-7954","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010602536","display_name":"Huajing Wang","orcid":"https://orcid.org/0009-0002-2291-3380","observed_orcids":["https://orcid.org/0009-0002-2291-3380"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huajing Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-2291-3380","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101434096","display_name":"Tengteng Li","orcid":"https://orcid.org/0009-0008-2416-1788","observed_orcids":["https://orcid.org/0009-0008-2416-1788","https://orcid.org/0000-0001-8167-4602"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tengteng Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-2416-1788","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032210639","display_name":"Yijing Ren","orcid":"https://orcid.org/0009-0004-8848-7630","observed_orcids":["https://orcid.org/0009-0004-8848-7630"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yijing Ren","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-8848-7630","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012459905","display_name":"Yunkai Zhang","orcid":"https://orcid.org/0000-0003-2490-5501","observed_orcids":["https://orcid.org/0000-0003-2490-5501","https://orcid.org/0009-0007-4932-6270"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yun-kai Zhang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2490-5501","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070905132","display_name":"Peng Chen","orcid":"https://orcid.org/0009-0007-0515-9618","observed_orcids":["https://orcid.org/0009-0007-0515-9618"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peng Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-0515-9618","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090336939","display_name":"Ao Sun","orcid":"https://orcid.org/0000-0002-3217-0149","observed_orcids":["https://orcid.org/0000-0002-3217-0149"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ao Sun","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3217-0149","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058255461","display_name":"Gang Bian","orcid":"https://orcid.org/0009-0008-1154-8764","observed_orcids":["https://orcid.org/0009-0008-1154-8764"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gang Bian","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-1154-8764","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021231933","display_name":"Bohua Li","orcid":"https://orcid.org/0000-0002-2867-7780","observed_orcids":["https://orcid.org/0000-0002-2867-7780","https://orcid.org/0009-0003-9473-9286"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bohua Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2867-7780","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109811084","display_name":"David A. Flowers","orcid":"https://orcid.org/0000-0002-7382-8461","observed_orcids":["https://orcid.org/0000-0002-7382-8461"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Flowers","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7382-8461","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090942128","display_name":"Marc Presler","orcid":"https://orcid.org/0000-0002-0182-8075","observed_orcids":["https://orcid.org/0000-0002-0182-8075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marc Presler","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0182-8075","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068865876","display_name":"Kalyanasundaram Subramanian","orcid":"https://orcid.org/0000-0001-9676-5427","observed_orcids":["https://orcid.org/0000-0001-9676-5427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kalyanasundaram Subramanian","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9676-5427","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018292858","display_name":"Jia Xue","orcid":"https://orcid.org/0000-0002-8048-752X","observed_orcids":["https://orcid.org/0000-0002-8048-752X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jia Xue","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8048-752X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081107325","display_name":"Jingjing Wang","orcid":"https://orcid.org/0000-0002-2259-4749","observed_orcids":["https://orcid.org/0000-0002-2259-4749"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jingjing Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2259-4749","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065280368","display_name":"Kevin Lynch","orcid":"https://orcid.org/0009-0000-5150-6579","observed_orcids":["https://orcid.org/0009-0000-5150-6579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Lynch","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-5150-6579","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001996286","display_name":"Jay M. Mei","orcid":"https://orcid.org/0009-0000-6211-4175","observed_orcids":["https://orcid.org/0009-0000-6211-4175"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jay Mei","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-6211-4175","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002022969","display_name":"Xiaowen He","orcid":"https://orcid.org/0009-0001-7985-5727","observed_orcids":["https://orcid.org/0009-0001-7985-5727"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaowen He","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-7985-5727","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033946409","display_name":"Bo Shan","orcid":"https://orcid.org/0009-0000-0269-8017","observed_orcids":["https://orcid.org/0009-0000-0269-8017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bo Shan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-0269-8017","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5048307356","display_name":"Bing Hou","orcid":"https://orcid.org/0000-0002-8348-3831","observed_orcids":["https://orcid.org/0000-0002-8348-3831"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bing Hou","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8348-3831","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9399999976158142},{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.9679999947547913},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6589999794960022},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.6079999804496765},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.5590000152587891},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7670000195503235},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.859000027179718},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9350000023841858},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.7559999823570251},{"id":"https://openalex.org/keywords/nonhuman-primates","display_name":"non-human primates","score":0.6439999938011169},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6209999918937683}],"concepts":[{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.7714726328849792},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.7168347835540771},{"id":"https://openalex.org/C502130503","wikidata":"https://www.wikidata.org/wiki/Q1089","display_name":"Palladium","level":3,"score":0.5711318254470825},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.5706283450126648},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5232107639312744},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5174713730812073},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.43142324686050415},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.37244904041290283},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3276742100715637},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.31933319568634033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2521713972091675},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.21015381813049316},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15920627117156982},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.13829660415649414},{"id":"https://openalex.org/C161790260","wikidata":"https://www.wikidata.org/wiki/Q82264","display_name":"Catalysis","level":2,"score":0.08321338891983032}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.c.7234905","doi":"https://doi.org/10.1158/0008-5472.c.7234905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.7234905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.c.7234905","doi":"https://doi.org/10.1158/0008-5472.c.7234905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.c.7234905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4392951990","https://openalex.org/W4306408085","https://openalex.org/W3212904207","https://openalex.org/W4388042446","https://openalex.org/W4308396334","https://openalex.org/W4402560921","https://openalex.org/W4396933420","https://openalex.org/W4378882731","https://openalex.org/W3180106521","https://openalex.org/W4213055507"],"abstract_inverted_index":{"Abstract":[0],"Immune":[1],"checkpoint":[2],"inhibitors":[3],"(ICI)":[4],"have":[5,35],"transformed":[6],"cancer":[7],"treatment.":[8],"However,":[9],"only":[10],"a":[11,16,44,61,74,99,239,265],"minority":[12],"of":[13,40,42,129,135,143,161,214,247,272,279],"patients":[14,20],"achieve":[15],"profound":[17],"response.":[18],"Many":[19],"are":[21],"innately":[22],"resistant":[23,55,119,249],"while":[24],"others":[25],"acquire":[26],"resistance":[27],"to":[28,56,122,195,230],"ICIs.":[29,123],"Furthermore,":[30],"hepatotoxicity":[31,190,271],"and":[32,52,70,79,140,186,203,233,250,276],"suboptimal":[33],"efficacy":[34],"hampered":[36],"the":[37,127,133,141,149,162,219,270],"clinical":[38,224],"development":[39],"agonists":[41,275],"4-1BB,":[43],"promising":[45],"immune-stimulating":[46],"target.":[47],"To":[48],"effectively":[49],"target":[50],"4-1BB":[51,71,274],"treat":[53],"diseases":[54],"ICIs,":[57],"we":[58],"engineered":[59],"ATG-101,":[60,215],"tetravalent":[62,255],"\"2+2\u2033":[63],"PD-L1\u00d74-1BB":[64,256],"bispecific":[65,257],"antibody.":[66],"ATG-101":[67,90,106,124,165,182,243,259],"bound":[68],"PD-L1":[69,96,204,240,266],"concurrently,":[72],"with":[73,87],"greater":[75],"affinity":[76],"for":[77,223],"PD-L1,":[78],"potently":[80],"activated":[81,91],"4-1BB+":[82,235,261],"T":[83,93,131,138,146,262],"cells":[84,94,147,237,263],"when":[85],"cross-linked":[86],"PD-L1\u2013positive":[88],"cells.":[89],"exhausted":[92],"upon":[95],"binding,":[97],"indicating":[98],"possible":[100],"role":[101],"in":[102,111,113,148,191,238,264],"reversing":[103],"T-cell":[104],"dysfunction.":[105],"displayed":[107],"potent":[108],"antitumor":[109,180],"activity":[110],"numerous":[112],"vivo":[114],"tumor":[115,150,157],"models,":[116],"including":[117],"those":[118],"or":[120],"refractory":[121,251],"greatly":[125],"increased":[126,179],"proliferation":[128],"CD8+":[130,144],"cells,":[132,139],"infiltration":[134],"effector":[136],"memory":[137],"ratio":[142],"T/regulatory":[145],"microenvironment":[151],"(TME),":[152],"rendering":[153],"an":[154,173],"immunologically":[155],"\u201ccold\u201d":[156],"\u201chot.\u201d":[158],"Comprehensive":[159],"characterization":[160],"TME":[163],"after":[164],"treatment":[166],"using":[167],"single-cell":[168],"RNA":[169],"sequencing":[170],"further":[171],"revealed":[172],"altered":[174],"immune":[175,236],"landscape":[176],"that":[177],"reflected":[178],"immunity.":[181],"was":[183],"well":[184],"tolerated":[185],"did":[187],"not":[188],"induce":[189],"non-human":[192],"primates.":[193],"According":[194],"computational":[196],"semimechanistic":[197],"pharmacology":[198],"modeling,":[199],"4-1BB/ATG-101/PD-L1":[200],"trimer":[201],"formation":[202],"receptor":[205],"occupancy":[206],"were":[207],"both":[208],"maximized":[209],"at":[210],"around":[211],"2":[212],"mg/kg":[213],"providing":[216],"guidance":[217],"regarding":[218],"optimal":[220],"biological":[221],"dose":[222],"trials.":[225],"In":[226],"summary,":[227],"by":[228,285],"localizing":[229],"PD-L1\u2013rich":[231],"microenvironments":[232],"activating":[234],"cross-linking\u2013dependent":[241,267],"manner,":[242,268],"safely":[244],"inhibits":[245],"growth":[246,278],"ICI":[248],"tumors.":[252,281],"Significance:":[253],"The":[254],"antibody":[258],"activates":[260],"minimizing":[269],"existing":[273],"suppressing":[277],"ICI-resistant":[280],"See":[282],"related":[283],"commentary":[284],"Ha":[286],"et":[287],"al.,":[288],"p.":[289],"1546":[290]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2024-05-16T00:00:00"}